PRESS RELEASE published on 04/02/2025 at 18:00, 2 months 15 days ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC Oxurion NV ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC waaruit blijkt verkoop van aandelen onder drempel. Meer informatie op www.oxurion.com Transparantiekennisgeving Oxurion NV Oftalmologische Therapieën Biofarmaceutisch Bedrijf Atlas Special Opportunities II LLC
PRESS RELEASE published on 04/02/2025 at 18:00, 2 months 15 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV, a biopharmaceutical company, received a transparency notification from Atlas Special Opportunities II, LLC regarding shareholding threshold crossing under Belgian legislation Transparency Notification Shareholding Threshold Oxurion NV Belgian Legislation Atlas Special Opportunities II LLC
BRIEF published on 03/27/2025 at 18:05, 2 months 21 days ago Oxurion reçoit une notification de transparence ajustée Actionnariat Notification De Transparence Oxurion Atlas Special Opportunities II Bourse De Bruxelles
BRIEF published on 03/27/2025 at 18:05, 2 months 21 days ago Oxurion receives adjusted transparency notification Transparency Notification Shareholding Oxurion Atlas Special Opportunities II Brussels Stock Exchange
PRESS RELEASE published on 03/27/2025 at 18:00, 2 months 21 days ago Oxurion ontvangt aangepaste transparantiekennisgeving van Atlas Special Opportunities II LLC Oxurion NV ontvangt aangepaste transparantiekennisgeving van Atlas Special Opportunities II LLC, waardoor zij onder de drempel (5%) komen. Meer informatie beschikbaar op www.oxurion.com Transparantiekennisgeving Oxurion NV Netvliesaandoeningen Biofarmaceutisch Bedrijf Atlas Special Opportunities II LLC
PRESS RELEASE published on 03/27/2025 at 18:00, 2 months 21 days ago Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV received an amended transparency notification from Atlas Special Opportunities II, LLC regarding the sale of voting securities. This press release replaces the one from March 18, 2025 Transparency Notification Euronext Brussels Oxurion NV Retinal Disease Therapies Atlas Special Opportunities II
BRIEF published on 03/24/2025 at 18:05, 2 months 24 days ago Oxurion Announces Capital Increase Following Convertible Bond Conversion Convertible Bonds Capital Increase Atlas Special Opportunities Ophthalmic Therapies Oxurion
BRIEF published on 03/24/2025 at 18:05, 2 months 24 days ago Oxurion annonce une augmentation de capital suite à la conversion d'obligations convertibles Obligations Convertibles Augmentation De Capital Thérapies Ophtalmiques Oxurion Opportunités Spéciales Atlas
PRESS RELEASE published on 03/24/2025 at 18:00, 2 months 24 days ago Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC converts bonds in Oxurion, resulting in EUR 150,000 capital increase. Oxurion focuses on developing therapeutics for vision care Capital Increase Therapeutics Vision Care Atlas Special Opportunities LLC Oxurion
PRESS RELEASE published on 03/24/2025 at 18:00, 2 months 24 days ago Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie Atlas Special Opportunities, LLC converte 6 obligaties in Oxurion, resulterend in EUR 150.000 kapitaalverhoging. Investering in innovatieve geneesmiddelen voor ouderen Euronext Brussel Kapitaalverhoging Atlas Special Opportunities Oxurion Innovatieve Geneesmiddelen
Published on 06/18/2025 at 15:15, 51 minutes ago Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging
Published on 06/18/2025 at 15:00, 1 hour 6 minutes ago iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025
Published on 06/18/2025 at 14:50, 1 hour 16 minutes ago Rio Grande Resources Announces Positive Assay Results From its Sampling and Field Campaign at the Winston Gold-Silver Project, New Mexico USA
Published on 06/18/2025 at 14:30, 1 hour 36 minutes ago Brenmiller Energy Comments on Reverse Share Split Ahead of Expected Near-Term Milestones
Published on 06/18/2025 at 14:30, 1 hour 36 minutes ago MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology
Published on 06/18/2025 at 15:30, 36 minutes ago Hong Kong Baptist University and Elsevier Report Highlights Global Expansion of Chinese Medicine Research, Urges Standardised Frameworks for Broader Integration
Published on 06/18/2025 at 15:29, 37 minutes ago Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 06/18/2025 at 15:28, 37 minutes ago Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 06/18/2025 at 15:27, 38 minutes ago Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc
Published on 06/18/2025 at 14:21, 1 hour 44 minutes ago Definitieve resultaten van de kapitaalverhoging
Published on 06/18/2025 at 09:39, 6 hours 26 minutes ago Eerste fase van het openbaar aanbod in het kader van een kapitaalverhoging is succesvol afgerond waarbij reeds werd ingeschreven op ongeveer 75,56% van de Nieuwe Aandelen Lancering van een versnelde private plaatsing van Scrips
Published on 06/18/2025 at 09:39, 6 hours 26 minutes ago First phase of the public offering in the framework of the capital increase has been successfully completed with about 75.56% of the New Shares already subscribed Launch of an accelerated private placement of Scrips
